Journal
AMERICAN JOURNAL OF HYPERTENSION
Volume 27, Issue 5, Pages 720-726Publisher
OXFORD UNIV PRESS
DOI: 10.1093/ajh/hpt177
Keywords
Vitamin D; uremia; cardiac hypertrophy; renin-angiotensin system; fibroblast growth factor; paricalcitol
Categories
Funding
- Fondo Nacional de Ciencia y Tecnologia (FONACIT), Venezuela [2005000283]
- National Institutes of Health [DK073183, HL085793]
- Clinical Practice Funds
Ask authors/readers for more resources
Vitamin D attenuates uremic cardiac hypertrophy, possibly by suppressing the myocardial reninangiotensin system (RAS) and fibroblast growth factors (FGFs). We compared the suppression of cardiac hypertrophy and myocardial expression of RAS and FGF receptor genes offered by the vitamin D analog paricalcitol (Pc) or the angiotensin-converting enzyme inhibitor enalapril (E) in experimental uremia. Rats with 5/6 nephrectomy received Pc or E for 8 weeks. Renal function, systolic blood pressure, and cardiac hypertrophy were evaluated. Myocardial expression of RAS genes, brain natriuretic peptide (BNP), and FGF receptor-1 (FGFR-1) were determined using quantitative reverse-transcription (pRT)-PCR. Blood pressure, proteinuria, and serum creatinine were significantly higher in untreated uremic animals. Hypertension was significantly reduced by E but only modestly by Pc; however, cardiac hypertrophy in the untreated group was similarly attenuated by Pc or E. Upregulation of myocardial expressions of renin, angiotensinogen, FGFR-1, and BNP in untreated uremic animals was reduced similarly by Pc and E, while the angiotensin II type 1 receptor was downregulated only by E. Uremic cardiac hypertrophy is associated with activation of the myocardial RAS and the FGFR-1. Downregulation of these genes induced by Pc and E results in similar amelioration of left ventricular hypertrophy despite the different antihypertensive effects of these drugs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available